Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

GU Cancers 2025 | Comparing cabozantinib to other TKIs in metastatic renal cell carcinoma

Martin Zarba • 14 Feb 2025
GU Cancers 2025
Genitourinary Cancer Kidney Cancer Cabozantinib Everolimus Lenvatinib

Martin Zarba, MD, Instituto Alexander Fleming, Buenos Aires, Argentina, discusses the role of cabozantinib in the treatment landscape, comparing it to other tyrosine kinase inhibitors (TKIs) in second-line metastatic renal cell carcinoma. While direct comparisons are limited, cabozantinib has demonstrated superiority over everolimus and may offer advantages over other TKIs like lenvatinib, particularly after prior TKI therapy. This interview took place at the ASCO GU Cancers Symposium 2025 in San Francisco, CA.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

More from Martin Zarba

Evaluating treatment options and the role of rechallenge in RCC
0:51
Evaluating treatment options and the role of rechallenge in RCC
Martin Zarba • 14 Feb 2025
Real-world efficacy of second-line cabozantinib in renal cell carcinoma
0:40
Real-world efficacy of second-line cabozantinib in renal cell carcinoma
Martin Zarba • 14 Feb 2025

Related Videos

Smoking-associated genomic alterations linked to poorer outcomes in metastatic prostate cancer
2:19
Smoking-associated genomic alterations linked to poorer outcomes in metastatic prostate cancer
Andrew Armstrong • 3 Jun 2026
Advances in next-generation PSMA-targeted radioligand therapy
2:09
Advances in next-generation PSMA-targeted radioligand therapy
Jeremie Calais • 1 Jun 2026
Toxicity considerations with actinium PSMA radioligand therapy in prostate cancer
2:22
Toxicity considerations with actinium PSMA radioligand therapy in prostate cancer
Jeremie Calais • 1 Jun 2026
Enzalutamide outcomes & duration predictors in mHSPC: ARCHES post hoc analyses
3:04
Enzalutamide outcomes & duration predictors in mHSPC: ARCHES post hoc analyses
Andrew Armstrong • 3 Jun 2026
The content of VJOncology is intended for healthcare professionals